COMMD1, from the Repair of DNA Double Strand Breaks, to a Novel Anti-Cancer Therapeutic Target

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy

(2020) Stephen A. Jannetti et al.   Frontiers in Pharmacology

European cancer mortality predictions for the year 2020 with a focus on prostate cancer

(2020) G. Carioli et al.   ANNALS OF ONCOLOGY

Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer

(2020) Amila Suraweera et al.   BRITISH JOURNAL OF CANCER

Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial

(2020) Ursula Nestle et al.   LANCET ONCOLOGY

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

(2020) Raju K. Vaddepally et al.   Cancers

COMMD1 regulates cell proliferation and cell cycle progression by modulating p21 Cip1 levels

(2019) Zhiwen Jiang et al.   BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY

Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy

(2019) Debarati Banik et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The role of combination chemo-immunotherapy in advanced non-small cell lung cancer

(2019) Danilo Rocco et al.   Expert Review of Anticancer Therapy

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

(2019) Narjust Duma et al.   MAYO CLINIC PROCEEDINGS

DNA-PKcs promotes chromatin decondensation to facilitate initiation of the DNA damage response

(2019) Huiming Lu et al.   NUCLEIC ACIDS RESEARCH

Combining immunotherapy and radiotherapy in lung cancer

(2018) Neeraj Bhalla et al.   Journal of Thoracic Disease

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016

(2018) et al.   JAMA Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions

(2018) Michal Zimmermann et al.   NATURE

Lung cancer: current therapies and new targeted treatments

(2017) Fred R Hirsch et al.   LANCET

Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN

(2017) Nausica Arnoult et al.   NATURE

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

DNA Ligase IV Guides End-Processing Choice during Nonhomologous End Joining

(2017) Michael P. Conlin et al.   Cell Reports

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

(2016) Scott Antonia et al.   LANCET ONCOLOGY

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

ATM Mutations in Cancer: Therapeutic Implications

(2016) M. Choi et al.   MOLECULAR CANCER THERAPEUTICS

Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer

(2016) Alina Fedoseienko et al.   PLoS One

Repair Pathway Choices and Consequences at the Double-Strand Break

(2016) Raphael Ceccaldi et al.   TRENDS IN CELL BIOLOGY

Classification of Non-Small Cell Lung Cancer Using Significance Analysis of Microarray-Gene Set Reduction Algorithm

(2016) Lei Zhang et al.   Biomed Research International

DNA damage foci: Meaning and significance

(2015) Kai Rothkamm et al.   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

Error-Prone Repair of DNA Double-Strand Breaks

(2015) Kasey Rodgers et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The 2015 World Health Organization Classification of Lung Tumors

(2015) William D. Travis et al.   Journal of Thoracic Oncology

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) M. Reck et al.   ANNALS OF ONCOLOGY

KPT-330 has antitumour activity against non-small cell lung cancer

(2014) H Sun et al.   BRITISH JOURNAL OF CANCER

Targeting DNA repair pathways for cancer treatment: what’s new?

(2014) Mark R Kelley et al.   Future Oncology

Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising

(2014) Christian Jekimovs et al.   Frontiers in Oncology

Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer

(2013) Balázs Győrffy et al.   PLoS One

Radiation Therapy for Early Stage Lung Cancer

(2013) Shruthi Arora et al.   SEMINARS IN INTERVENTIONAL RADIOLOGY

Charting the Landscape of Tandem BRCT Domain-Mediated Protein Interactions

(2012) N. T. Woods et al.   Science Signaling

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

(2011) Sara Simonetti et al.   Journal of Translational Medicine

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

COMMD1 disrupts HIF-1α/β dimerization and inhibits human tumor cell invasion

(2010) Bart van de Sluis et al.   JOURNAL OF CLINICAL INVESTIGATION

The DNA Damage Response: Making It Safe to Play with Knives

(2010) Alberto Ciccia et al.   MOLECULAR CELL

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE